See more : Far East Wind Power Corp. (FEWP) Income Statement Analysis – Financial Results
Complete financial analysis of Shanghai Junshi Biosciences Co., Ltd. (1877.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shanghai Junshi Biosciences Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Kintech Electronics Co., Ltd. (6210.TWO) Income Statement Analysis – Financial Results
- Biffa plc (BIFF.L) Income Statement Analysis – Financial Results
- FLSmidth & Co. A/S (FLIDF) Income Statement Analysis – Financial Results
- KuangChi Science Limited (0439.HK) Income Statement Analysis – Financial Results
- GME Resources Limited (GMRSF) Income Statement Analysis – Financial Results
Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
About Shanghai Junshi Biosciences Co., Ltd.
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.50B | 1.45B | 4.02B | 1.59B | 775.09M | 934.00K | 1.15M | 3.76M | 2.89M | 5.80M |
| Cost of Revenue | 667.29M | 526.28M | 1.26B | 372.53M | 90.68M | 267.00K | 446.00K | 986.00K | 132.69K | 3.69M |
| Gross Profit | 835.26M | 927.21M | 2.77B | 1.22B | 684.41M | 667.00K | 702.00K | 2.77M | 2.75M | 2.11M |
| Gross Profit Ratio | 55.59% | 63.79% | 68.74% | 76.64% | 88.30% | 71.41% | 61.15% | 73.76% | 95.40% | 36.43% |
| Research & Development | 1.94B | 2.38B | 2.07B | 1.78B | 946.10M | 538.18M | 275.30M | 122.00M | 0.00 | 29.69M |
| General & Administrative | 556.81M | 578.27M | 647.95M | 443.35M | 244.23M | 124.84M | 73.75M | 42.76M | 83.85M | 42.83M |
| Selling & Marketing | 844.36M | 715.70M | 734.56M | 687.97M | 320.06M | 20.30M | 0.00 | 0.00 | 0.00 | 1.57M |
| SG&A | 1.40B | 1.29B | 1.38B | 1.13B | 564.29M | 145.14M | 73.75M | 42.76M | 83.85M | 44.40M |
| Other Expenses | -11.01M | -34.19M | -91.89M | -18.56M | -31.55M | 17.02M | 47.42M | -13.68M | 0.00 | 0.00 |
| Operating Expenses | 3.29B | 3.64B | 3.36B | 2.89B | 1.48B | 684.79M | 346.44M | 151.08M | 74.82M | 37.79M |
| Cost & Expenses | 3.96B | 4.17B | 4.62B | 3.26B | 1.57B | 685.06M | 346.89M | 152.07M | 74.95M | 41.48M |
| Interest Income | 99.43M | 61.02M | 30.98M | 20.28M | 29.22M | 3.88M | 2.65M | 3.07M | 13.32M | 11.20M |
| Interest Expense | 29.01M | 29.37M | 21.83M | 29.39M | 13.30M | 2.08M | 25.37M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 303.22M | 293.65M | 262.56M | 151.36M | 59.59M | 30.21M | 18.32M | 8.66M | 7.12M | 2.95M |
| EBITDA | -2.16B | -2.38B | -422.77M | -1.53B | -704.85M | -649.28M | -302.43M | -136.58M | -73.97M | -39.33M |
| EBITDA Ratio | -143.60% | -163.60% | -10.50% | -95.79% | -90.94% | -69,516.06% | -24,156.79% | -3,635.45% | -2,562.50% | -677.91% |
| Operating Income | -2.46B | -2.67B | -685.33M | -1.68B | -764.44M | -679.49M | -295.64M | -145.24M | -81.09M | -42.29M |
| Operating Income Ratio | -163.55% | -183.81% | -17.03% | -105.28% | -98.63% | -72,750.11% | -25,752.53% | -3,865.85% | -2,809.07% | -728.83% |
| Total Other Income/Expenses | -32.44M | -3.58M | 59.00K | -1.04M | -24.24M | -38.23M | 25.00M | 17.06M | 22.35M | 2.66M |
| Income Before Tax | -2.49B | -2.68B | -592.65M | -1.67B | -763.12M | -717.71M | -320.74M | -131.25M | -58.74M | -24.48M |
| Income Before Tax Ratio | -165.71% | -184.05% | -14.72% | -104.68% | -98.46% | -76,842.93% | -27,939.37% | -3,493.45% | -2,034.79% | -421.91% |
| Income Tax Expense | 44.00M | -93.11M | 135.53M | -3.82M | -18.89M | -1.21M | 58.00K | 241.00K | 769.82K | 775.19K |
| Net Income | -2.28B | -2.58B | -728.18M | -1.67B | -744.23M | -716.41M | -321.07M | -131.97M | -57.97M | -25.25M |
| Net Income Ratio | -151.85% | -177.65% | -18.09% | -104.44% | -96.02% | -76,703.85% | -27,967.86% | -3,512.56% | -2,008.12% | -435.27% |
| EPS | -2.32 | -2.81 | -0.82 | -2.03 | -0.96 | -1.19 | -0.42 | -0.17 | -0.26 | -0.12 |
| EPS Diluted | -2.32 | -2.81 | -0.82 | -2.02 | -0.95 | -1.19 | -0.42 | -0.17 | -0.26 | -0.12 |
| Weighted Avg Shares Out | 985.30M | 917.47M | 890.01M | 821.97M | 778.56M | 601.92M | 760.31M | 760.31M | 222.96M | 214.93M |
| Weighted Avg Shares Out (Dil) | 985.30M | 917.47M | 892.66M | 824.82M | 783.62M | 601.92M | 760.31M | 760.31M | 222.96M | 214.93M |
Source: https://incomestatements.info
Category: Stock Reports